Newsletter of the NIH Rare Diseases Clinical Research Network
Volume 2, Issue 1. Spring 2011

www.RareDiseasesNetwork.org

In This Issue

Welcome

Spotlight on an RDCRN Consortium: CINCH

How Does A Rare Disease Consortium Work?

Urea Cycle Disorders Consortium Benefits from CTSA Leverage

Coalition of Patient Advocacy Groups (CPAG) in the Spotlight

The Office of Rare Diseases Research (ORDR)

RDCRN Opens 30 New Studies for Patient Accrual

About Spotlight

Past Issues

 

Rare Diseases Headlines:

NIH Researchers Identify genetic cause of new vascular disease – Rare disease is the first discovered in Undiagnosed Diseases Program
>> More

Statement Issued from the 2nd Meeting of the International Rare Diseases Research Consortium
>> More

Featured Event:

Rare Diseases Day 2011
>> More

Spotlight Announcements / Calendar of Events

Joubert Syndrome Biennial Conferences: Advancing Translational Ciliopathy Research, July 13, 2011 - July 16, 2011

International Meeting on Genetic Syndromes of the Ras/MAPK Pathway, July 29, 2011 - July 31, 2011

End of Life Palliative Care National Science Summit, August 10, 2011 - August 12, 2011

>> View More News and Events

The Office of Rare Diseases Research (ORDR)

The Office of Rare Diseases Research (ORDR) is the parent entity overseeing the RDCRN network. It was established in 1993 within the Office of the Director of the National Institutes of Health (NIH), the Federal focal point for health research. ORDR coordinates and supports rare diseases research, responds to research opportunities for rare diseases, and provides information on rare diseases. In 2002, the Congress and President Bush established ORDR and its responsibilities in statute by enacting and signing Public Law 107–280, The Rare Diseases Act of 2002.

What Does ORDR Do?

Dr. Stephen Groft

 

 

Stephen C. Groft, Pharm.D,
Director of NIH's Office of
Rare Diseases Research
(ORDR)